Product Overview
[Drug Name]
Generic Name: Cerebroprotein Hydrolysate Tablets
Trade Name: Gulixi Cerebroprotein Hydrolysate Tablets 13mg: 28.8mg x 24 tablets
[Main Ingredients]
This product is a hydrolyzed peptide extracted from fresh brain tissue of healthy pigs. It contains various amino acids, cephalins, phosphatidylcholine, and peptide nerve growth factor.
[Properties]
This product is a film-coated tablet. After removing the film coating, it is brown-yellow in color.
[Indications/Main Functions]
It is used to relieve symptoms such as insomnia, headache, memory loss, dizziness, and irritability. It can also promote recovery from sequelae of traumatic brain injury, sequelae of cerebrovascular disease, sequelae of encephalitis, acute cerebral infarction, and acute brain trauma.
[Specifications]
13mg: 28.8mg x 24 tablets
[Dosage and Administration]
Oral, three times daily. Adults: 1-2 tablets per dose. Children: Reduce dosage or follow a doctor's advice.
[Adverse Reactions]
No adverse reactions have been reported.
[Contraindications]
1. Contraindicated in patients with severe renal impairment. 2. Contraindicated in pregnant or lactating women. 3. Contraindicated in patients with allergic reactions to this product.
[Drug Interactions]
1. When taken concurrently with antidepressants, it is recommended to reduce the dosage of the latter. 2. Concomitant use with monoamine oxidase inhibitors may result in additive effects.
[Precautions]
1. Use with caution in patients with allergies. 2. Do not use if the drug's properties have changed.
[Pediatric Use]
Children should reduce the dosage of this drug or follow a doctor's advice. Other safety considerations are unknown.
[Elderly Use]
Elderly patients are the primary target population for this drug, but its safety profile has not been definitively documented. Close observation is recommended during clinical use, and appropriate dosage reductions or follow a doctor's advice are recommended.
[Overdose]
Overdose of this drug may cause euphoria or nervousness, which resolves upon discontinuation of the drug.
[Pharmacology and Toxicology]
This drug is a peptidergic neurotrophic drug specific to the brain. It acts on the central nervous system in various ways, regulating and improving neuronal metabolism, promoting synaptic formation, inducing neuronal differentiation, and further protecting nerve cells from various ischemic and neurotoxin damage. It can penetrate the blood-brain barrier, promote protein synthesis in the brain, influence the respiratory chain, protect against hypoxia, and improve brain energy metabolism. It activates adenylate cyclase and catalyzes other hormone systems, providing neurotransmitters, peptide hormones, and coenzyme precursors.
